Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MOLN.SW
- Price
- 3.23
- Stock movement up
- +0.14 (4.69%)
- Company name
- Molecular Partners AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Market cap
- 119.25M
- Ent value
- 68.93M
- Price/Sales
- 19.87
- Price/Book
- 0.86
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 1.57%
- 1 year return
- -9.64%
- 3 year return
- -45.05%
- 5 year return
- -29.52%
- 10 year return
- -18.64%
Last updated: 2025-04-12
DIVIDENDS
MOLN.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 19.87 |
| Price to Book | 0.86 |
| EV to Sales | 11.48 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 36.86M |
| EPS (TTM) | -1.89 |
| FCF per share (TTM) | -1.79 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.00M |
| Gross profit (TTM) | -33.10M |
| Operating income (TTM) | -63.07M |
| Net income (TTM) | -62.59M |
| EPS (TTM) | -1.89 |
| EPS (1y forward) | -2.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -551.47% |
| Operating margin (TTM) | -1050.83% |
| Profit margin (TTM) | -1042.84% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 65.75M |
| Net receivables | 3.32M |
| Total current assets | 149.53M |
| Goodwill | 0.00 |
| Intangible assets | 82.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 154.21M |
| Accounts payable | 2.38M |
| Short/Current long term debt | 2.75M |
| Total current liabilities | 10.44M |
| Total liabilities | 15.43M |
| Shareholder's equity | 138.78M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -58.46M |
| Capital expenditures (TTM) | 896.00K |
| Free cash flow (TTM) | -59.35M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -45.10% |
| Return on Assets | -40.59% |
| Return on Invested Capital | -44.71% |
| Cash Return on Invested Capital | -42.40% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.04 |
| Daily high | 3.25 |
| Daily low | 3.00 |
| Daily Volume | 32K |
| All-time high | 38.40 |
| 1y analyst estimate | 9.75 |
| Beta | 0.54 |
| EPS (TTM) | -1.89 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Apr 2025 |
Downside potential
Loading...
Downside potential data
| MOLN.SW | S&P500 | |
| Current price drop from All-time high | -91.58% | -12.89% |
| Highest price drop | -92.19% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -51.90% | -11.07% |
| Avg time to new high | 119 days | 12 days |
| Max time to new high | 2373 days | 1805 days |
COMPANY DETAILS
Marketcap
119.25M
Marketcap category
Small-cap
Description
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Employees
167
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend ...
April 3, 2025
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer Firs...
March 25, 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-...
March 25, 2025
Despite challenges with collaborations, Molecular Partners AG (MLLCF) maintains a strong cash position and advances its promising pipeline.
March 8, 2025
DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on Radio-DARPins now expanded to ten programsMP0533 Phase 1/2...
March 6, 2025
Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Fe...
February 28, 2025
Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Ora...
January 12, 2025
New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the partie...
January 12, 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...
December 17, 2024
The consensus price target hints at an 80.7% upside potential for Molecular Partners AG Sponsored ADR (MOLN). While empirical research shows that this sought-after metric is hardly effective, an upwar...
December 13, 2024
Next page